{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:40:44Z","timestamp":1792726844281,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ihj.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:21:35Z","timestamp":1781763695000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical Management of Hypertrophic Cardiomyopathy"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2857-0975","authenticated-orcid":false,"given":"Mohit D.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vrinda","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Girish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2026.06.005_bib1","first-page":"e1239","article-title":"AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy","volume":"149","author":"Ommen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.ihj.2026.06.005_bib2","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2026.06.005_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.124.014023","article-title":"Medical, surgical, and interventional management of hypertrophic cardiomyopathy","volume":"18","author":"Massera","year":"2025","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.ihj.2026.06.005_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ihj.2026.06.005_bib8","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of mavacamten in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.06.005_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ihj.2026.06.005_bib10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy referred for septal reduction therapy (VALOR-HCM)","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.ihj.2026.06.005_bib11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"et al.; ODYSSEY-HCM Investigators. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.06.005_bib4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/0735-1097(93)90386-F","article-title":"A double-blind placebo-controlled crossover trial of nadolol and verapamil in hypertrophic cardiomyopathy","volume":"21","author":"Gilligan","year":"1993","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.06.005_bib5","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.jacc.2021.07.065","article-title":"Effect of metoprolol in patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Dybro","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.ihj.2026.06.005_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jacc.2022.10.020","article-title":"et al.; REDWOOD-HCM Steering Committee and Investigators. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy","volume":"81","author":"Maron","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.06.005_bib6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"8 Suppl","key":"10.1016\/j.ihj.2026.06.005_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0735-1097(23)01053-7","article-title":"et al.; REDWOOD-HCM Cohort 4 Investigators. Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (REDWOOD-HCM Cohort 4)","volume":"81","author":"Masri","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.06.005_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten versus metoprolol in obstructive hypertrophic cardiomyopathy (MAPLE-HCM)","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.06.005_bib15","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten in obstructive hypertrophic cardiomyopathy (SEQUOIA-HCM)","volume":"391","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ihj.2026.06.005_bib16","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.jacc.2024.09.002","article-title":"Standard-of-care medication withdrawal in patients receiving aficamten in FOREST-HCM","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ihj.2026.06.005_bib17","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2601103","article-title":"et al.; SCOUT-HCM Investigators. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy","author":"Rossano","year":"2026","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.ihj.2026.06.005_bib18","first-page":"S13","article-title":"SONATA-HCM: study design of a phase III trial of sotagliflozin in symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy","volume":"30","author":"Day","year":"2024","journal-title":"J Card Fail"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483226001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483226001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:26:16Z","timestamp":1792725976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483226001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":18,"alternative-id":["S0019483226001094"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2026.06.005","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Management of Hypertrophic Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}